Delivery Order SPE2DB22D2009-SPE2DB25FM1KF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded a delivery order valued at $12,175.85 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This competitively awarded, firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order falls under...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.60 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is being performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) valued at $1,740.04 under a firm fixed-price contract type. This delivery order, which has an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,283.02 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $2,957.94 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price delivery order was issued on a non-set-aside basis and represents a pediatric ADHD medication supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $2,566.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), with an ultimate completion date of August 4, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed and...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1KFDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,978.37 for Quillivant XR 25 mg/5 ml suspension (60 ml) with a firm fixed price structure. This non-set-aside, competitively awarded contract was executed on September 9, 2025, with an ultimate completion date of September 10, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. As a primary vendor under the DLA Troop Support Medical IDC, the company supplies an extensive portfolio of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The current delivery order for Quillivant XR—an attention deficit/hyperactivity disorder medication—exemplifies the company's role in fulfilling specialized pharmaceutical requirements for military medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 9/9/25 |